Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fixed-dose versus free combination valsartan + amlodipine for 24-hour ambulatory blood pressure control
IRCT20221016056199N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of valsartan and amlodipine in essential hypertension (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Average 24-hour systolic blood pressure, Average 24-hour diastolic blood pressure and 4 more. Started Dec 2022; status: completed.
02
Drugs
valsartanamlodipine
03
Conditions
essential hypertension
Beyond the preview
Go deeper on IRCT20221016056199N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221016056199N1.